ASCO GU 2022

ADC in bladder cancer: defining the future!

Neoadjuvant therapy in UTUC: Good options for selected patients

Role of PARPi in urothelial cancer

PARPi in urothelial cancer: DFS advantage for the DDR+, OS data pending.

ADC shape the therapy landscape in urothelial cancer

Patient selection for bladder preservation

Exciting data supports trimodality therapy

ADCs will be step-changing in urothelial cancers

Follow-up data confirm OS benefit across subgroups

Not practice changing, but hypothesis generating.

HER2 ERBB2 – entering precision oncology

Patient selection for adjuvant Nivolumab (TPS vs. CPS)

Ongoing immunotherapy innovation for mCRPC

IO escalation results in improved response in met. TCC.

Mature data confirm efficacy of maintenance avelumab as standard of care

Enza beyond progression? Practice changing or not?

Triplet vs. doublet: Which patients should we consider?

Theranostics – Presence and future: Vision, PSMAfore, PSMAAddition, TheraP

Do we need testing? Which biomarkers are of relevance?

The future of genetic testing. Somatic vs. germline? International perspectives

Is biomarker development taking a back seat in prostate cancer?

Subgroup analyses confirm the importance of oral daily GnRH Antagonist - relugolix

PSA response correlates with OS and benefits in QoL

Where do PROpel and Magnitude agree?

Is the dual hormone-backbone the future?

Is docetaxel still needed for hormone sensitive mCRPC?

The importance of conducting HCRA

How to improve PSMA based radioligand therapy

PRESIDE indicates benefit of continuation ENZA + ADT

New therapies and molecular targets in prostate cancer

DARO in triplet therapy for CRPC

Addition of darolutamide improves OS in met. hormone-sensitive PC

Should we use arbiraterone and niraparib as 1st line treatment of mCRPC with BRCA1/2 mutation?

HRR testing: MAGNITUDE vs. PROpel

Exciting new compound for mCRPC

Should we use arbiraterone and olaparib as 1st line treatment of mCRPC?

The need for biomarker panels in biopsy decision making

PSMA and FDG PET as biomarkers for response to LuPSMA

PROpel & Magnitude: who wins the race?

Triplet-therapy as a novel treatment option

Thoughts on first line treatment options following ASCO GU 2022

Neoadjuvant IO+TKI Treatment: We need more data on efficient IO/TKI combinations

Adjuvant PD1 Therapy confirms significant benefit for high-risk patients. An individual risk benefit assessment is required!

Treatment options following adjuvant PD1 Therapy: Uncertainty of choices!

Consistent OS benefit confirmed. Consider overtreatment vs. undertreatment!

Microbioma modification and checkpoint inhibition

Data gap in 2nd line RCC: what’s new?

Update in adjuvant therapy for kidney cancer

Nivo montoherapy followed by Nivi-Ipi resuce

Update in neoadjuvant therapy for kidney cancer

CheckMate final OS Follow Up and health related QoL

Frontline treatment of metastatic kidney cancer

Neoadjuvant avelumab/axitinib - NeoAvAx

Adjuvant Pembroluzimab update in kidney cancer